Medical Therapeutics

iMEDD, Inc.

Brief Description

Drug delivery based on micro-engineering technology utilizing silicon microcapsules with nanofilters so that treatments can be controlled and targeted to particular cells and sites in the body.

The company licensed intellectual property that had been previously licensed to UC Berkeley spinout Iris Micromedical. The IP was developed in the lab of UC Berkeley Associate Professor of Engineering Mauro Ferrari, who moved to Ohio State University in 1999 as a professor of bioengineering, internal medicine, and mechanical engineering. In conjunction with Dr....

DNA Sciences, Inc.

Brief Description

While gene sequencing and gene expression technologies have become relatively industrialized, genetic analysis is a time-consuming, labor intensive, and rate-limiting step in drug discovery. DNA Sciences, Inc. removed this bottleneck by developing a high-throughput system that miniaturizes and automates genotyping.

The company's genotyping technology relied on microchannel electrophoretic DNA separation technology combined with fluorescent detection of PCR-amplified DNA. The company licensed the technology from Amersham Pharmacia Biotech Ltd. (Uppsala, Sweden) and...

Dahlia Biosciences

Brief Description Dahlia Biosciences is leading the development of cell-based RNA detection tools using CRISPR technology. The foundational RNA-targeting Cas9 technology was invented by Dr. Mitchell O’Connell and Dr. Sam Sternberg in the laboratory of Dr. Jennifer Doudna at UC Berkeley.

The company's vision is to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells.

Timeline 2011. Company founded Inventors

Jennifer Doudna, Mitchell O'Connell, Benjamin Oakes,...

MRL Bio

Brief Description

The company is developing a unique drug delivery platform for tissue regeneration in acute and chronic wounds.

Timeline 2019. Company founded Inventors

Phillip Messersmith, Jing Cheng, Ellen Heber-Katz

Lymphax, Inc.

Brief Description

Lymphax, Inc. is a therapeutics company treating ocular diseases and conditions.

Formerly known as NewVision Bioscience, Inc.

Timeline 2019. Company founded Inventors

Lu Chen, Sammy Grimaldo, Meng Shi, Don Yuen

Laguna Bio

Brief Description

Developer of drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company specializes in providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of a bispecific antibody drug, enabling patients to survive a deadly disease like cancer.

Timeline 2022. Company founded Inventors

Daniel Portnoy, Thomas Patrick Burke, Juliana Durack, Jonathan Lewis Portman, Christopher Rae, Rafael Jose Rivera Lugo, Kimberly Makiko Sogi, Sarah Ann Stanley,...

Axent Biosciences

Brief Description

Axent Biosciences is a pre-clinical stage biotechnology company developing next generation stem cell therapies to address unmet medical needs in human diseases/disorders. The company was spun out of research discoveries in the lab of UC Berkeley Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience David Schaffer. Axent's platform technologies in stem cell manufacturing and implantation leverage 20+ years of stem cell expertise and 10+ years of biomaterials engineering to overcome major bottlenecks in the clinical development...

Berkeley BioSciences Inc.

Brief Description

Berkeley BioSciences, Inc. is a molecular immunology and oncology company with two divisions: biopharmaceutical and nutraceutical. It is researching and developing therapeutics and nutritional products based on patented naturally-occurring and biologically optimized phytonutrients with potent immune modulating and anti-cancer properties. The company was founded by Dr. Gary Firestone, former Chairman of the Nutritional Sciences Department and NIH Director of Cancer Research at UC Berkeley. The company's first...

Exelixis, Inc.

Brief Description

Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, the company established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. The company developed CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and partnered with leading...

Opus Biosciences

Brief Description

The mission of Opus Biosciences is to advance the field of lipid nanoparticle delivery through the development of safer, higher efficacy, cost effective, and exceedingly efficient LNPs, surpassing industry standards. Opus is committed to unlocking existing limitations within the drug delivery space by enabling more frequent re-dosing, reducing toxicity, and improving and expanding therapeutic targets. The foundational technology was invented in the lab of Bioengineering Professor Niren Murthy at the UC Berkeley Innovative Genomics Institute.

Timeline 2023....